Capsaicin (TRPV1 agonist) therapy for pain relief: Farewell or revival?

Clinical Journal of Pain

Volumn 24, Issue 2, 2008, Pages 142-154

  Knotkova, Helena ^a   Pappagallo, Marco ^b   Szallasi, Arpad ^c,d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MONMOUTH MEDICAL CENTER   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Capsaicin; Desensitization; Resiniferatoxin; Selective neurotoxicity; TRPV1 receptor

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ADLEA; ALDEA; ANALGESIC AGENT; CAPSAICIN; CAPSAICIN DERIVATIVE; CIS CAPSAICIN; NGX 4010; PLACEBO; RTX; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 AGONIST;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; BURN; CANCER PAIN; CLINICAL TRIAL; CLUSTER HEADACHE; DESENSITIZATION; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; MIGRAINE; MYOFASCIAL PAIN; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN THRESHOLD; PATIENT COMPLIANCE; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RHEUMATOID ARTHRITIS; SENSORY NERVE CELL; SINGLE DRUG DOSE; STUMP PAIN; TENNIS ELBOW;

ANALGESICS; ANIMALS; CAPSAICIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; HUMANS; HYPERALGESIA; MOLECULAR STRUCTURE; PAIN, INTRACTABLE; SENSORY SYSTEM AGENTS; TRPV CATION CHANNELS;

EID: 38549118896     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318158ed9e     Document Type: Review

References (153)

1. Ramsey LS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol. 2006;68:619-647.
2. Huang J, Zhang X, McNaughton PA. Modulation of temperaturesensitive TRP channels. Semin Cell Develop Biol. 2006;17:638-645.
3. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003;112:819-829.
4. Caterina MJ, Rosen TA, Tominaga M, et al. A capsaicin receptor homologue with a high threshold for noxious heat. Nature. 1999;398:436-441.
5. Brauchi S, Orta G, Salazaar M, et al. A heat-sensing cold receptor: C-terminal domain determines thermosensation in transient receptor potential channels. J Neurosci. 2006;26:4835-4840.
6. Weil A, Moore SE, Waite SJ, et al. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRPV1 and TRPM8. Mol Pharmacol. 2005;68:518-527.
7. Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007. [Epub ahead of print].
8. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol. 2004; 500:231-241.
9. Malmberg AB, Bley KR. Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation. Basel: Birkhauser; 2005.
10. Pingle SC, Matta JA, Ahern GP. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handbook Exp Pharmacol. 2007;179:153-169.
11. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
12. Maggi CA, Meli A. The sensory-efferent function of capsaicinsensitive sensory neurons. Gen Pharmacol. 1988;19:1-43.
13. Szolcsányi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides. 2004;38:377-384.
14. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000;288:306-313.
15. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 2000;405:183-187.
16. Bölcskei K, Helyes ZS, Szabó A, et al. Investigation of the role of TRPV1 in acute and chronic nociceptive processes using genedeficient mice. Pain. 2005;117:368-376.
17. Christoph T, Grunweller A, Mika J, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biophys Biochem Res Comm. 2006;350:238-243.
18. Perry L, Dickau R, Zarrillo S, et al. Starch fossils and the domestication and dispersal of Chili peppers (Capsicum spp. L.) in the Americas. Science. 2007;315:986-988.
19. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159-212.
20. Mason L, Moore A, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. Br Med J. 2004;328:991-997.
21. Ma W, Quirion R. Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets. 2007;11:307-320.
22. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Disc. 2007;6:357-372.
23. Immke DC, Gavva NR. The TRPV1 receptor and nociception. Semin Cell Develop Biol. 2007. [Epub ahead of print].
24. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature. 2000;408:985-990.
25. Vellani V, Mapplebeck S, Moriondo A, et al. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol. 2001;534:813-825.
26. Mohapatra DP, Nau C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem. 2003;278:50080-50090.
27. Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature. 2001;411:957-962.
28. Bhave G, Gereau RW IV. Posttranslational mechanisms of peripheral sensitization. J Neurobiol. 2004;61:88-106.
29. Roberts LA, Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Patents on CNS Drug Disc. 2006;1:65-76.
30. Hicks GA. TRP channels as therapeutic targets: hot property, or time to cool down? Neurogastroenterol Motil. 2006;18:590-594.
31. Baamonde A, Lastra A, Juarez L, et al. TRPV1 desensitization and endogenous vanilloid involvement in the enhanced analgesia induced by capsaicin in inflamed tissues. Brain Res Bull. 2005;67:476-481.
32. Mózsik G, Vincze A, Szolcsányi J. Four response stages of capsaicin-sensitive primary afferent neurons to capsaicin and its analogs: gastric acid secretion, gastric mucosal damage and protection. J Gastroenterol Hepatol. 2001;16:1093-1097.
33. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci. 2001;24:487-517.
34. Tominaga M, Tominaga T. Structure and function of TRPV1. Pfluger's Arch. 2005;451:143-150.
35. Suh YG, Oh U. Activation and activators of TRPV1 and their pharmacological implications. Curr Pharm Des. 2005;11:2687-2698.
36. Cortright DN, Krause JE, Broom DC. TRP channels and pain. Biochim Biophys Acta. 2007. [Epub ahead of print].
37. Szolcsányi J, Joó F, Jancsó-Gábor A. Mitochondrial changes in preoptic neurons after capsaicin desensitization of the hypothalamic thermodetectors in rats. Nature. 1971;229:116-117.
38. Macho A, Calzado MA, Munoz-Blanco J, et al. Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ. 1999;6:155-165.
39. Jancsó G, Király E, Jancsó-Gábor A. Pharmacologically induced selective degeneration of chemosensitive primary sensory neurons. Nature. 1977;270:741-743.
40. Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998;18:8947-8959.
41. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135-145.
42. Silva C, Avelino A, Souto-Moura C, et al. A light- and electronmicroscopic histopathological study of human bladder mucosa after intravesical resiniferaroxin application. BJU Int. 2001;88:355-360.
43. Brown DC, Iadarola MJ, Perkowski SZ, et al. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103:1052-1059.
44. Menendez L, Juarez L, Garcia E, et al. Analgesic effects of capsaicin and resiniferatoxin on bone cancer pain in mice. Neurosci Lett. 2006;393:70-73.
45. Bonnington JK, McNaughton PA. Signalling pathways involved in the sensitization of mouse nociceptive neurons by nerve growth factor. J Physiol. 2003;551:433-436.
46. 2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMO-dependent protein kinase. J Biol Chem. 2005;280:13424-13432.
47. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem. 2004;279:25665-25672.
48. Hellwig N, Albrecht N, Harteneck C, et al. Homo- and heteromeric assembly of TRPV channel subunits. J Cell Sci. 2005;118:917-928.
49. Vetter I, Wyse BD, Monteith GR, et al. The μ opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase. A pathway. Mol Pain. 2006;2:22-26.
50. Patwardhan AM, Jeske NA, Price JT, et al. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA. 2006;103:11393-11398.
51. Binzen U, Greffrath W, Henessy S, et al. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience. 2006;142:527-539.
52. Fristad I, Berggen E, Haug SR. Delta opioid receptors in small and medium-sized trigeminal neurons supporting the dental pulp of rats. Arch Oral Biol. 2006;51:273-281.
53. Högesatt ED, Jönsson BAG, Ermund A, et al. Coversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280:31405-31412.
54. Rawls SM, Ding Z, Cowan A. Role of TRPV1 and cannabinoid CB1 receptors in AM404-evoked hypothermia in rats. Pharmacol Biochem Behav. 2006;83:508-516.
55. Costa B, Siniscalco D, Trovato AE, et al. AM404, and inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol. 2006;148:1022-1032.
56. Sutton KG, Garrett EM, Rutter AR, et al. Functional characterization of the S512Y mutant vanilloid human TRPV1 receptor. Br J Pharmacol. 2005;146:702-711.
57. Phillips E, Reeve A, Bevan S, et al. Identification of species-specific determination of the action of the antagonists capsazepine and the agonists PPAHV on TRPV1. J Biol Chem. 2004;279:17165-17172.
58. Kedei N, Szabó T, Lile JD, et al. Analysis of the quaternary structure of vanilloid receptor 1. J Biol Chem. 2002;276:28613-28619.
59. Garcia-Sanz N, Fernandez-Carjaval A, Morenilla-Palao C, et al. Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J Neurosci. 2004;24:5307-5314.
60. Xue Q, Yu K, Trilk S, et al. The genomic organization of the gene encoding the vanilloid receptor: evidence for multiple splice variants. Genomics. 2001;76:14-20.
61. Wang G, Hu HZ, Colton CK, et al. An alternative splicing product of the murine trpv1 gene dominant negatively modulates the activity of the TRPV1 channel. J Biol Chem. 2004;279:37423-37430.
62. Lu G, Henderson D, Liu L, et al. TRPV1b: a functional human vanilloid receptor splice variant. Mol Pharmacol. 2005;67:1119-1127.
63. Tian W, Wang DH, Cohen DM. Regulation of TRPV1 by a novel renally expressed TRPV1 splice variant. Am J Physiol Renal Physiol. 2006;290:F117-F126.
64. 2+-sensitive interaction of the vanilloid receptor TRPV1 with tubulin. J Neurochem. 2004;91:1092-1103.
65. Donnerer J, Liebmann I, Schicho R. Differential regulation of 3-beta-hydroxysteroid dehydrogenase and vanilloid receptor TRPV1 mRNA in sensory neurons by capsaicin and NGF. Pharmacology. 2005;73:97-101.
66. Ueda H. Molecular mechanisms of neuropathic pain-phenotype switch and initiation mechanisms. Pharmacol Ther. 2006;109:57-77.
67. Xu XJ, Farkas-Szallasi T, Lundberg JM, et al. Effects of the capsaicin analogue resiniferatoxin on spinal nociceptive mechanisms in the rat: behavioral, electrophysiological and in situ hybridization studies. Brain Res. 1997;752:52-60.
68. Broberger C, Farkas-Szallasi T, Szallasi A, et al. Increased spinal cholecystokinin activity after systemic resiniferatoxin: electrophysiological and in situ hybridization studies. Pain. 2000;84:21-28.
69. Szallasi A. Vanilloid-sensitive neurons: a fundamental subdivision of the peripheral nervous system. J Periph Nerv Syst. 1996;1:6-18.
70. Cruz F. Mechanisms involved in new therapies for overactive bladder. Urology. 2004;63:65-73.
71. Lazzeri M, Spinelli M, Zanollo A, et al. Intravesical vanilloid and neurogenic incontinence: ten years experience. Urol Int. 2004;72:145-149.
72. Amaya S, Shimosato G, Nagano M, et al. NGF and GNDF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. Eur J Neurosci. 2004;20:2303-2310.
73. Wilson-Gerwing TD, Dmyterko MV, Zochodne DW, et al. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci. 2005;25:758-767.
74. Stein AT, Ufret-Vincenty CA, Hua L, et al. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol. 2006;128:509-522.
75. Miller MS, Buck SH, Sipes IG, et al. Regulation of substance P by nerve growth factor: disruption by capsaicin. Brain Res. 1982;250:193-196.
76. Otten U, Lorez HP, Businger F. Nerve growth factor antagonizes the neurtoxic action of capsaicin on primary sensory neurons. Nature. 1983;301:515-517.
77. Carlton SM, Coggeshall RE. Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. Neurosci Lett. 2001;310:53-56.
78. Lauria G, Morbin M, Lombardi R, et al. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Periph Nerv Syst. 2006;11:262-271.
79. Lukacs V, Thyagarajan B, Varnai P, et al. Dual regulation of TRPV1 by phopshoinositides. J Neurosci. 2007;27:7070-7080.
80. Ständer S, Moorman C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage origin. Exp Dermatol. 2004;13:129-139.
81. Bodó E, Biró T, Telek A, et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol. 2005;166:985-998.
82. Li WH, Lee YM, Kim JY, et al. Transient receptor potential vanilloid-1 mediates heat shock-induced matrix metalloproteinase-1 expression in human epidermal keratinocytes. J Invest Dermatol. 2007. [Epub ahead of print].
83. Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007;7:11-18.
84. Yao X, Garland CJ. Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res. 2005;97:853-863.
85. Vriens J, Janssen A, Prenen J, et al. TRPV channels and modulation by hepatocyte growth factor/scatter factor in human hepatoblastoma (HepG2) cells. Cell Calcium. 2004;36:19-28.
86. Schwarz EC, Wolfs MJ, Tonner S, et al. TRP channels and lymphocytes. Handb Exp Pharmacol. 2007;179:445-456.
87. Biró T, Maurer M, Modarres S, et al. Characterization of functional vanilloid receptors expressed by mast cells. Blood. 1998;91:1332-1340.
88. Szallasi A, Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 2000;23:491-497.
89. Marsch R, Foeller E, Rammes G, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci. 2007;27:832-839.
90. Suri A, Szallasi A. The emerging role of TRPV1 and diabetes and obesity. Trends Pharmacol Sci. 2007. In press.
91. + sensory neurons control β cell stress and islet inflammation in autoimmune diabetes. Cell. 2006;127:1123-1135.
92. Yiangou Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001;357:1338-1339.
93. Chan CL, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet. 2003;361:385-391.
94. Tympanidis P, Casula MA, Yiangou Y, et al. Increased vanilloid receptor VR1 innervation of vulvodynia. Eur J Pain. 2004;8:129-133.
95. Matthews PJ, Aziz Q, Facer P, et al. Increased capsaicin receptor TRPV1 nerve fibers in the inflamed human oesophagus. Eur J Gastroenterol Hepatol. 2004;16:897-902.
96. Gopinath P, Wan E, Holdcroft A, et al. Increased capsaicin receptor TRPV1 in skin nerve fibers and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain. BMC Women's Health. 2005;5:2-6.
97. Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med. 2006;12:545-554.
98. Biró T, Modarres S, Blumberg PM. Differential activation and desensitization of sensory neurons by resiniferatoxin. J Neurosci. 1997;17:5622-5628.
99. Szolcsányi J, Szallasi A, Szallasi Z, et al. Resiniferatoxin, an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. J Pharmacol Exp Ther. 1990;255:923-928.
100. Szallasi A, Blumberg PM, Anicelli LL, et al. The cloned rat vanilloid receptor VR1 mediates both R-type binding and C-type calcium response in dorsal root ganglion neurons. Mol Pharmacol. 1999;56:581-587.
101. Kissin I, Freitas CF, Bradley EL. Perineural resiniferatoxin prevents the development of hyperalgesia produced by loose ligation of the sciatic nerve in rats. Anesth Analg. 2007;104:1210-1116.
102. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49:574-579.
103. Tandan R, Lewis GA, Krushinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow up. Diabetes Care. 1992;15:8-14.
104. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Pediatr Med Assoc. 1991;81:288-293.
105. Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther. 1995;12:111-120.
106. Basha KM, Whitehouse FW. Capsaicin: a therapeutic option for painful diabetic neuropathy. Henry Ford Hosp Med J. 1991;39:138-140.
107. Low PA, Opfer-Gehrking TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain. 1995;62:163-168.
108. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991-998.
109. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in postherpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7:317-328.
110. Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. DICP. 1991;25:381-387.
111. Zhang WY, Wan L, Po A. The effectiveness of topically applied capsaicin. A metaanalysis. Eur J Clin Pharmacol. 1994;46:517-522.
112. Letendre S, Ellis RJ. Neurologic complications of HIV disease and their treatments. Topics HIV Med. 2006;14:21-26.
113. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg. 1998;86:579-583.
114. Saper JR, Klapper J, Mathew NT, et al. Intranasal civamide for the treatment of episodic cluster headaches. Arch Neurol. 2002;59:990-994.
115. Diamond S, Freitag F, Phillips SB, et al. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia. 2000;20:597-602.
116. Available at: http://www.neurogeskx.com
117. Davis J, Williams H, Bramlett K, et al. Enduring and well-tolerated analgesia for total knee arthroplasty postsurgical pain produced by a single, rapidly-eliminated, intraoperative instillation of 4975. J Pain. 2007;8:S46.
118. Cantillon M, Vause E, Sykes D, et al. Safety, tolerability and efficacy of intraoperative ALGRX 4975 in a randomized, double-blind, placebo-controlled study of subjects undergoing bunionectomy. J. Pain. 2005;6:S48.
119. Richards PT, Vasko G, Stasko I, et al. ALGRX 4975 reduces pain of acute lateral epicondylitis: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J. Pain. 2006;7:S3.
120. Diamond E, Richards PT, Miller T. ALGRX 4975 reduces pain of intermetatarsal neuroma: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J Pain. 2006;7:S41.
121. Aasvang EK, Hansen JB, Malmstrøm J, et al. Effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain. Anesthesiology. 2007;107:A459.
122. Cantillon M, Vause E, Sykes D, et al. Preliminary safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. J Pain. 2005;6:S39.
123. Cantillon M, Vause E, Sykes D, et al. Safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. J Pain. 2005;6:S39.
124. Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle controlled study. Arch Intern Med. 1991;151:2225-2229.
125. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehiclecontrolled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510-526.
126. Bernstein JE, Bickers DR, Dahl MV, et al. Treatment of chronic postherpetic neuralgia with topical capsaicin. A preliminary study. Am Acad Dermacol. 1987;17:93-96.
127. Fusco BM, Alessandri M. Analgesic effect of capsaicin in idiopathic trigeminal neuralgia. Anesth Analg. 1992;74:375-377.
128. Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol. 1994;77:135-140.
129. Rayner HC, Atkins RC, Westerman RA. Relief of local stump pain by capsaicin cream. Lancet. 1989;2:1276-1277.
130. Weintraub M, Golik A, Rubio A. Capsaicin for treatment of posttraumatic amputation stump pain. Lancet. 1990;336:1003-1004.
131. Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain. 1989;5:49-53.
132. Marks DR, Papoport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalagia. 1993;13:114-116.
133. Markley HG. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep. 2003;7:139-143.
134. Fusco BM, Barzoi G, Agro F. Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anesth. 2003;90:812-815.
135. Levy RL. Intranasal capsaicin for acute abortive treatment of migraine without aura. Headache. 1995;35:277-281.
136. Rapoport AM, Bigal ME, Tepper SJ, et al. Intranasal medications for the treatment of migraine and cluster headache. Neurosci Lett. 2005;384:150-155.
137. Ko F, Diaz M, Smith P, et al. Toxic effects of capsaicin on keratinocytes and fibroblasts. J Burn Care Rehabil. 1998;19:409-413.
138. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol. 1992;19:604-607.
139. Winocur E, Gavish A, Halachmi M, et al. Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area. J Orofac Pain. 2000;14:31-36.
140. Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992;51:375-379.
141. Dini D, Bertelli G, Gozza A, et al. Treatment of the postmastectomy pain syndrome with topical capsaicin. Pain. 1993;54:223-226.
142. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. J Pain Symptom Manage. 1995;10:243-248.
143. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997;15:2974-2980.
144. Shim WS, Tak MH, Lee MH, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci. 2007;27:2331-2337.
145. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care. 1992;15:159-165.
146. Fusco BM, Marabini S, Maggi CA, et al. Preventive effect of repeated nasal application of capsaicin in cluster headache. Pain. 1994;59:321-325.
147. Stovner LJ, Sjaastad O. Treatment of cluster headache and its variants. Curr Opin Neurol. 1995;8:243-247.
148. Cheng J, Yang XN, Zhang SP. Capsaicin for allergic rhinitis in adults (review). Cochrane Library. 2007;1:1-12.
149. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain. 2000;4:355-360.
150. Wist E, Risberg T. Topical capsaicin in treatment of hyperalgesia, allodynia and dysesthetic pain caused by malignant tumor infiltration to the skin. Acta Oncol. 1993;32:343-345.
151. Gidal B, Billington R. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006;12:S269-S278.
152. Rashid MH, Inoue M, Kondo S, et al. Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther. 2003;304:940-948.
153. Davis KD, Meyer RA, Turnquist JL, et al. Cutaneous injection of the capsaicin analogue, NE-21,610, produces analgesia to heat but not to mechanical stimuli in man. Pain. 1995;61:17-26.